Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach
| Autor: | Panayotis Kaloyannidis, Eshrak Al Shaibani, Asif Moinnudin, Khalid Al Anezi, Hani Al Hashmi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Hematology Reports, Vol 13, Iss 1 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2038-8322 2038-8330 |
| DOI: | 10.4081/hr.2021.8780 |
| Popis: | For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|